|
Lorus Therapeutics isn't talking nonsense, they're talking antisense. The biotechnology firm is developing cancer drugs using antisense technology, which prevents cells from producing disease-causing proteins and may cause fewer side effects than traditional chemotherapies. It is testing its lead candidate in this area, LOR-2040, as a treatment for various blood cancers and solid tumors. Lorus is working in other areas of cancer research as well, developing some traditional therapies, as well as immunotherapies, which stimulate the body's immune system to fight cancer. The company licensed its Virulizin immunotherapy, a potential treatment for pancreatic cancer, to a subsidiary of Zoticon Bioventures in 2008.
|
| | | Contact Information | |
Address: |
2 Meridian Rd.
Toronto, Ontario M9W 4Z7, Canada
| | Phone: | 416-7981200 | | Fax: | 416-7982200 |
|
| Financial
Highlights | | Fiscal Year End: | May | | Revenue (2009): | 0.20 M | | Revenue Growth (1 yr): | 288.70% | | Employees (2008): | 26 | | Employee Growth (1 yr): | (-13.30%) |
|
|
Key People
| | • |
Chairman:
Dennis Burger
| | • |
Director, President and CEO:
Aiping H. Young
| | • |
Director Finance and Acting CFO:
Elizabeth Williams
|
|
|
